Related Experiment Videos
Atypical antipsychotics in the managed care era
A D Loebel1, S R Botts, B I Feldman
1Albert Einstein College of Medicine, Bronx, NY, USA.
The American Journal of Managed Care
|December 8, 1997
Summary
New atypical antipsychotics offer significant long-term benefits for schizophrenia treatment, potentially reducing overall healthcare costs despite higher initial prices. These advanced medications are becoming first-line treatments.
Area of Science:
- Psychiatry and Pharmacology
Background:
- A new class of atypical antipsychotic drugs has emerged for schizophrenia treatment.
- These represent a major advancement since the 1950s, with increasing use as first-line agents.
Purpose of the Study:
- To review the role of atypical antipsychotics in schizophrenia management.
- To compare their efficacy and cost-effectiveness against conventional medications.
Main Methods:
- Review of current literature on atypical antipsychotics.
- Pharmacoeconomic analysis of treatment costs and benefits.
Main Results:
- Atypical antipsychotics show promise for improved long-term outcomes when used early in schizophrenia.
- Despite higher acquisition costs, they may reduce the overall financial burden of the illness.
Conclusions:
- Atypical antipsychotics are a significant therapeutic development in schizophrenia.
- Their early adoption may lead to better patient outcomes and potential cost savings.